Hydroxychloroquine hitting the headlines-retinal considerations.

Downes, Susan M; Leroy, Bart P; Sharma, Srilakshmi M; Sivaprasad, Sobha; Dollfus, Hélène

Downes, Susan M; Leroy, Bart P; Sharma, Srilakshmi M; Sivaprasad, Sobha; Dollfus, Hélène.

Downes SM; Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK. susan.downes@eye.ox.ac.uk.
Leroy BP; Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. susan.downes@eye.ox.ac.uk.
Sharma SM; Department of Ophthalmology & Centre for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium.
Sivaprasad S; Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Dollfus H; Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.

Eye (Lond) ; 34(7): 1158-1160, 2020 07.

Article in English | MEDLINE | ID: covidwho-824521

Subject(s)

Antirheumatic Agents; COVID-19 Drug Treatment; Hydroxychloroquine; Retina; Retinal Diseases; Antirheumatic Agents/adverse effects; Humans; Retina/drug effects; Retinal Diseases/drug therapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Retina / Retinal Diseases / Antirheumatic Agents / COVID-19 Drug Treatment / Hydroxychloroquine Limits: Humans Language: English Journal: Eye (Lond) Journal subject: Ophthalmology Year: 2020 Document Type: Article Affiliation country: S41433-020-0934-9

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google